A 58-year-old woman with chronic kidney disease (CKD Stage 4, eGFR 22 mL/min/1.73m²) and hepatic cirrhosis presents for elective hip arthroplasty. During induction, she receives propofol and fentanyl. For neuromuscular blockade, the anesthesiologist administers rocuronium 0.6 mg/kg IV. After 45 minutes of surgery, neuromuscular monitoring (train-of-four) shows 1 out of 4 responses. What is the PRIMARY reason for prolonged neuromuscular blockade in this patient?

Explanation

## Prolonged Neuromuscular Blockade in Renal and Hepatic Failure **Key Point:** Rocuronium's elimination depends on both hepatic metabolism (60%) and renal excretion (40%). In a patient with CKD Stage 4 and cirrhosis, both pathways are severely impaired, leading to drug accumulation and prolonged blockade. ### Rocuronium Pharmacokinetics ```mermaid flowchart TD A[Rocuronium administered IV]:::action --> B{Elimination pathways}:::decision B -->|60% Hepatic metabolism| C[Liver: CYP3A4 metabolism]:::outcome B -->|40% Renal excretion| D[Kidney: Glomerular filtration]:::outcome C --> E[Cirrhosis impairs hepatic clearance]:::urgent D --> F[CKD Stage 4 impairs renal clearance]:::urgent E --> G[Drug accumulation]:::urgent F --> G G --> H[Prolonged neuromuscular blockade]:::outcome ``` ### Comparison of Muscle Relaxants in Organ Failure | Agent | Type | Hepatic Metabolism | Renal Excretion | Best in Renal/Hepatic Failure? | | --- | --- | --- | --- | --- | | **Rocuronium** | Non-depolarising | 60% | 40% | **NO** — Both pathways impaired | | **Atracurium** | Non-depolarising | Minimal | Minimal | **YES** — Hofmann + ester hydrolysis | | **Cisatracurium** | Non-depolarising | Minimal | Minimal | **YES** — Organ-independent | | **Succinylcholine** | Depolarising | Plasma pseudocholinesterase | — | **NO** — Pseudocholinesterase deficiency in cirrhosis | | **Vecuronium** | Non-depolarising | 75% | 25% | **NO** — Hepatic-dependent | **High-Yield:** In patients with combined renal and hepatic failure, **atracurium or cisatracurium** are the agents of choice because they undergo organ-independent elimination (Hofmann elimination and ester hydrolysis). Rocuronium, vecuronium, and succinylcholine should be avoided. **Clinical Pearl:** Train-of-four monitoring showing 1/4 response indicates profound neuromuscular blockade. In this patient, rocuronium should not have been used; atracurium or cisatracurium would have allowed predictable recovery despite organ failure. ### Why This Patient Is at High Risk for Prolonged Blockade 1. **CKD Stage 4 (eGFR 22):** Severely reduced glomerular filtration; rocuronium's 40% renal excretion is impaired 2. **Hepatic cirrhosis:** Reduced hepatic metabolism; rocuronium's 60% hepatic clearance is impaired 3. **Hypoproteinaemia in cirrhosis:** Reduced plasma protein binding may increase free drug concentration (though rocuronium is not highly protein-bound) 4. **Cumulative effect:** Both elimination pathways are blocked, causing exponential drug accumulation **Mnemonic:** **RACK in organ failure** — **R**ocuronium is **A**voided, **C**isatracurium/atracurium are **C**hosen, **K**idney and liver both impaired.